7,778 results match your criteria Leukemia Research[Journal]


Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.

Leuk Res 2019 Apr 13;81:43-49. Epub 2019 Apr 13.

University of Colorado Division of Hematology, Aurora, CO, United States. Electronic address:

Background: Patients with relapsed and refractory (R/R) acute myeloid leukemia (AML) have limited treatment options. Genomically-defined personalized therapies are only applicable for a minority of patients. Therapies without identifiable targets can be effective but patient selection is challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.04.005DOI Listing

Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.

Leuk Res 2019 Mar 27;81:35-42. Epub 2019 Mar 27.

Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland. Electronic address:

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, leading to hematopoietic precursor cell apoptosis and peripheral blood cytopenias. Anemia is the most frequently experienced cytopenia and is the main cause of MDS symptoms, with fatigue and dyspnea contributing to reduced quality of life and increased morbidity. As MDS disease course and prognosis is influenced by disease factors, prognostic scoring systems have been developed for MDS to aid clinical and therapeutic decisions following diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.006DOI Listing

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.

Leuk Res 2019 Apr 9;81:27-34. Epub 2019 Apr 9.

Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, 1081HV Amsterdam, the Netherlands. Electronic address:

Leukemic stem cells (LSCs), defined by CD34/CD38 expression, are believed to be essential for leukemia initiation and therapy resistance in acute myeloid leukemia. In addition, the side population (SP), characterized by high Hoechst 33342 efflux, reflecting therapy resistance, has leukemia initiating ability. The purpose of this study is, in both CD34-positive and CD34-negative AML, to integrate both types of LSC compartment into a new more restricted definition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.04.004DOI Listing

Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.

Leuk Res 2019 Apr 8;81:19-24. Epub 2019 Apr 8.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Beijing 100730, People's Republic of China. Electronic address:

Objective: To summarize the clinical features and outcomes in Chinese patients with immunoglobulin light-chain (AL) amyloidosis with ≥10% bone marrow plasma cells (BMPCs).

Methods: We retrospectively compared the clinical features and outcomes between patients with ≥10% BMPCs (high-BMPC group; n = 56) and those with <10% BMPCs (low-BMPC group; n = 311).

Results: Patients in the high-BMPC group had significantly higher levels of N-terminal pro-brain natriuretic peptide, significantly lower levels of 24 h urine protein, and significantly higher levels of difference between the involved and uninvolved serum free light chains (485. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126193006
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2019.04.002DOI Listing
April 2019
2 Reads

Compound mutations in CML-imaginary bogeyman or real arch-nemesis?

Authors:
David T Yeung

Leuk Res 2019 Apr 6. Epub 2019 Apr 6.

South Australian Health and Medical Research Institute, Royal Adelaide Hospital and Adelaide Medical School, Room 7E.314, Royal Adelaide Hospital Port Road, Adelaide, SA, 5000, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.011DOI Listing

Relevant updates in systemic mastocytosis.

Leuk Res 2019 Apr 4;81:10-18. Epub 2019 Apr 4.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address:

Systemic Mastocytosis (SM) is a rare myeloproliferative neoplasm (MPN) that is characterized by a clonal proliferation of mast cells (MCs). The symptoms and clinical presentation of SM are the result of both MC proliferation as well as activation and degranulation, causing hyperactive and over-exaggerated hypersensitivity responses, as well as organ infiltration by pathogenic MCs. The clinical presentation and course of SM is varied and organ involvement can lead to significant morbidity and mortality in some cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.04.001DOI Listing
April 2019
1 Read

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

Leuk Res 2019 Apr 4;81:1-9. Epub 2019 Apr 4.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States; Department of Medical Oncology, Mayo Clinic 200 First St. SW, Rochester, MN, 55905.

The infusion of autograft absolute lymphocyte and monocyte counts affect survival in patients undergoing autologous peripheral hematopoietic stem cell transplantation (APHSCT). However, the specific autograft immune effector cells affecting survival post-APHSCT are unknown. Thus, we performed an ad hoc analysis from our published double-blind, randomized phase III clinical trial in non-Hodgkin's lymphoma (NHL) patients, looking at the infused autograft immune effector cells and their relationship with clinical outcomes post-APHSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.009DOI Listing
April 2019
4 Reads

Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Leuk Res 2019 May 28;80:40-42. Epub 2019 Mar 28.

Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee 53226, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.007DOI Listing
May 2019
4 Reads

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Leuk Res 2019 May 18;80:33-39. Epub 2019 Mar 18.

Department of Haematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.

Therapeutic decision making is often challenging in older AML patients. We collected retrospective data of 355 consecutive AML patients (≥60 years) who were treated with intensive chemotherapy (IC) (n = 155), hypomethylating agents (HMA) (n = 83), or best supportive care (BSC) (n = 117) between 2002 and 2017. Overall survival (OS) and response rates after therapy were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.004DOI Listing

High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients.

Leuk Res 2019 May 20;80:26-32. Epub 2019 Mar 20.

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:

B-cell acute lymphoblastic leukemia (B-ALL) in adults remains a highly challenging disease. Identifying new prognostic biomarkers is necessary to help select the best therapeutic schedules and to improve prognosis. We performed bioinformatics analyses of transcriptomic data to identify aberrantly-expressed mRNA transcripts in B-ALL and focused on RASD1 (Ras-related dexamethasone-induced 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.005DOI Listing
May 2019
1 Read

Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018.

Leuk Res 2019 May 20;80:19-25. Epub 2019 Mar 20.

Hematology Unit, IRCSS, Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147, Genoa, Italy. Electronic address:

The bone marrow failure (BMF) syndromes are a group of rare disorders characterized by ineffective hematopoiesis resulting from deficiencies in the hematopoietic stem cell compartment. Although these diseases are typically acquired, some forms (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.003DOI Listing
May 2019
2 Reads

Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.

Leuk Res 2019 May 2;80:11-18. Epub 2019 Mar 2.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address:

Purpose: Myelodysplastic syndromes (MDS) are characterized by variable degrees of clinical outcomes. Until now, hypomethylating agents (HMAs) are the only drugs that have been approved by FDA in remedying this complicated prognosis disease, but without satisfactory outcome. So, biomarkers of better clinical outcome are of great significance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.001DOI Listing
May 2019
1 Read

Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.

Leuk Res 2019 May 28;80:1-10. Epub 2019 Feb 28.

Division of Hematology, University of Colorado Medical Center, Aurora, CO, USA.

Iron metabolism is altered in a variety of cancers; however, little is known about the role of iron metabolism in the biology and response to therapy of acute myeloid leukemia (AML). Here we show that SLC40A1, the gene encoding the iron exporter ferroportin (FPN), is variably expressed among primary AMLs and that low levels are associated with good prognosis and improved outcomes. In particular, core binding factor (CBF) AMLs, which are associated with good outcomes with chemotherapy, consistently have low level of SLC40A1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.011DOI Listing
May 2019
1 Read
2.351 Impact Factor

Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.

Leuk Res 2019 Apr 19;79:60-68. Epub 2019 Feb 19.

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Olomouc, Czech Republic. Electronic address:

Background: Better risk-stratification of patients with chronic lymphocytic leukemia (CLL) and identification of subsets of ultra-high-risk (HR)-CLL patients are crucial in the contemporary era of an expanded therapeutic armamentarium for CLL.

Methods: A multivariate patient similarity network and clustering was applied to assess the prognostic values of routine genetic, laboratory, and clinical factors and to identify subsets of ultra-HR-CLL patients. The study cohort consisted of 116 HR-CLL patients (F/M 36/80, median age 63 yrs) carrying del(11q), del(17p)/TP53 mutations and/or complex karyotype (CK) at the time of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.005DOI Listing
April 2019
2 Reads

Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.

Leuk Res 2019 Apr 28;79:52-59. Epub 2019 Feb 28.

Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA.

Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors. In hematologic malignancies, there is limited information except for Hodgkin's lymphoma, and there is even less information regarding myeloproliferative neoplasm (MPN). Therefore, we explored this by first measuring PD-1 and PD-L1 levels (percentage of positive cells) in 63 patients with Philadelphia chromosome-negative MPN (Ph(-) MPN), including 16 MF (12 PMF, 2 post-PV-MF, 2 post-ET-MF), 29 ET, and 18 PV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.010DOI Listing
April 2019
1 Read
2.351 Impact Factor

Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.

Leuk Res 2019 Apr 23;79:45-51. Epub 2019 Feb 23.

Department of Medical Oncology, Amsterdam, the Netherlands. Electronic address:

Chemoresistance is an important factor in the treatment failure of childhood acute lymphoblastic leukemia (ALL). One underlying mechanism of chemoresistance involves (over)expression of ATP-dependent drug efflux transporters such as multidrug resistance protein 1-5 (MRP1-5) and breast cancer resistance protein (BCRP), which can extrude the important antileukemia drug methotrexate (MTX). Survival of childhood ALL critically depends on the leukemic blasts' capacity for intracellular retention of MTX and MTX-polyglutamates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.008DOI Listing
April 2019
6 Reads

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Leuk Res 2019 Apr 28;79:38-44. Epub 2019 Feb 28.

Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA. Electronic address:

Glasdegib is a potent and selective oral inhibitor of the Hedgehog pathway. We report data from the single-arm, lead-in cohort of an open-label phase 1b/2 trial of glasdegib in patients with primary/secondary myelofibrosis (MF) previously treated with at least one Janus kinase inhibitor (JAKi). Patients received glasdegib 100 mg orally once daily until there was no further clinical benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.012DOI Listing
April 2019
8 Reads

The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.

Leuk Res 2019 Apr 22;79:34-37. Epub 2019 Feb 22.

Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China. Electronic address:

Hemorrhage is the typical manifestation of APL-related coagulopathy while thrombosis is infrequently reported. In a retrospective analysis with 33 patients with hyperleukocytic APL, we found 6 out of 33 hyperleukocytic APL patients presented with thrombosis rather than hemorrhage. A notable feature in these high-risk APL patients with thrombosis is that there were no significant abnormalities in fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126193003
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2019.02.007DOI Listing
April 2019
14 Reads

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.

Leuk Res 2019 Apr 23;79:27-33. Epub 2019 Feb 23.

Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. Electronic address:

Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Combining consolidative chemotherapy with TKIs may increase rates of infectious complications, organ toxicity, hospitalization, and non-relapse mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.009DOI Listing
April 2019
3 Reads

Replicative senescence of hematopoietic cells in patients with idiopathic cytopenia of undetermined significance.

Leuk Res 2019 Apr 18;79:22-26. Epub 2019 Feb 18.

Department of Laboratory Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. Electronic address:

We hypothesized that a subset of idiopathic cytopenia of undetermined significance (ICUS) is associated with an increased autonomous proliferation with exhaustion of hematopoiesis. The aim of this study was to investigate the cell turnover rate and replicative history of the bone marrow cells of ICUS patients. To this end, we examined telomere length (TL), proliferation, and apoptosis of the bone marrow cells of ICUS patients and healthy controls (HCs) using telomere quantitative fluorescence in situ hybridization and immunohistochemical staining for Ki-67 and cleaved caspase-3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.004DOI Listing
April 2019
1 Read

Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource.

Leuk Res 2019 May 22;80:43-44. Epub 2019 Feb 22.

Department of Medicine, Division of Hematology, Stanford Cancer Institute, Institute of Stem Cell and Regenerative Medicine, Stanford University School of Medicine, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.006DOI Listing

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.

Leuk Res 2019 Apr 15;79:17-21. Epub 2019 Feb 15.

Department of Internal Medicine - Hematology and Oncology, University Hospital and Faculty of Medicine, Jihlavská 20, 625 00 Brno, Czech Republic; CEITEC, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.

Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line therapy in patients with CLL and significant comorbidities in real hematological practice. Eighty-three consecutive patients with cumulative illness rating scale (CIRS) >6 who received at least one cycle of BR as first-line treatment were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.002DOI Listing
April 2019
4 Reads

Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.

Leuk Res 2019 Apr 24;79:6-16. Epub 2019 Jan 24.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address:

The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.012DOI Listing
April 2019
1 Read

Chronic myeloid leukemia: Two mysteries.

Leuk Res 2019 Apr 12;79:3-5. Epub 2019 Feb 12.

Haematology Research Centre, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.003DOI Listing

The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.

Leuk Res 2019 Apr 11;79:1-2. Epub 2019 Feb 11.

Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.001DOI Listing
April 2019
1 Read

Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world.

Leuk Res 2019 Apr 24;79:69-74. Epub 2019 Jan 24.

Laboratorio de Citometria y Biologia Molecular, Departamento Basico de Medicina, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. Electronic address:

Background: Flow cytometry (FC) is a valuable tool for the diagnosis of myelodysplastic syndromes (MDS). We present results of a survey carried out to evaluate FC current practice for MDS diagnosis in Latin America (LA), focusing on markers used and characteristics of the clinical diagnostic report. Compliance to IMDSflow recommendations was also evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.009DOI Listing
April 2019
1 Read

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.

Leuk Res 2019 Mar 24;78:45-51. Epub 2019 Jan 24.

Winship Cancer Institute of Emory University, Atlanta, GA, Georgia.

Intensive treatment for newly diagnosed acute myelogenous leukemia (ND-AML) patients are reserved for "fit" patients. While guidelines recommend evaluation of age, performance status and comorbidities, there is no consensus on the definition of "fitness" or optimal therapy for elderly AML patients. This retrospective study evaluated characteristics and survival outcomes of 274 patients (age ≥60 years) with ND-AML treated with 7 + 3 (cytarabine + an anthracycline) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.008DOI Listing
March 2019
7 Reads

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 in Ph+ CML.

Leuk Res 2019 Mar 28;78:36-44. Epub 2018 Dec 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria. Electronic address:

In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I. Treatment with ponatinib may suppress most of these mutants, including T315I, but is also associated with a high risk of clinically relevant side effects. We screened for alternative treatment options employing available tyrosine kinase inhibitors (TKI) in combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.013DOI Listing
March 2019
2 Reads

Should patient age be an obstacle for high-dose therapy and stem cell rescue?

Authors:
Eldad J Dann

Leuk Res 2019 Mar 25;78:34-35. Epub 2019 Jan 25.

Rambam Health Care Campus, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.010DOI Listing

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Leuk Res 2019 Mar 17;78:29-33. Epub 2019 Jan 17.

The University of Alabama at Birmingham, Birmingham, AL, United States.

Purpose: To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia.

Patients And Methods: We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolled between 2002 and 2009 into two parallel cooperative group clinical trials SWOG S0106/ECOG-ACRIN E1900. Institutions were classified as low- (LAIs) (≤ 9 enrolled patients) or high-accruing institutions (HAIs) (≥10 enrolled patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.007DOI Listing
March 2019
8 Reads

A registry-based analysis of survival outcomes in mast cell leukemia.

Leuk Res 2019 Mar 16;78:24-28. Epub 2019 Jan 16.

University of Rochester, Department of Radiation Oncology, 601 Elmwood Avenue, Rochester, NY, 14642, United States. Electronic address:

Introduction: Mast cell leukemia (MCL) is rare and carries a poor prognosis. No standard-of-care has been established. No USA registry-based analyses have examined clinical correlates of overall survival (OS) in MCL patients, thus we aimed to do this using the Surveillance, Epidemiology, and End Results (SEER) database, and the National Cancer Database (NCDB). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126193000
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2019.01.005DOI Listing
March 2019
15 Reads

STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype.

Leuk Res 2019 Mar 15;78:21-23. Epub 2019 Jan 15.

Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.004DOI Listing
March 2019
2 Reads

Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.

Leuk Res 2019 Mar 15;78:12-20. Epub 2019 Jan 15.

Department of Cell Biology and Medical Genetics, School of Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China; Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, USA. Electronic address:

Acute myeloid leukemia (AML) is a heterogeneous group of fast growing cancers of myeloid progenitor cells, for which effective treatments are still lacking. Identification of signaling inhibitors that block their proliferation could reveal the proliferative mechanism of a given leukemia cell, and provide small molecule drugs for targeted therapy for AML. In this study, kinase inhibitors that block the majority of cancer signaling pathways are evaluated for their inhibition of two AML cell lines of the M5 subtypes, CTV-1 and THP-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.006DOI Listing
March 2019
1 Read
2.351 Impact Factor

Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.

Leuk Res 2019 Apr 6;79:75-80. Epub 2019 Jan 6.

Hôpital Maisonneuve-Rosemont, Division of Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Transplant Program, Université de Montréal, Montréal, Québec, Canada. Electronic address:

Background: Autologous hematopoietic stem cell transplantation (AHSCT) in the older population is associated with an increased risk of morbidity and mortality. Determination of the hematopoietic cell transplant comorbidity index (HCT-CI) has contributed to improve patient selection while allowing prediction of their non-relapse mortality (NRM). The goal of this study was to identify factors influencing both safety and efficacy of AHSCT in an older non-Hodgkin lymphoma (NHL) population to better select those who will benefit from this intervention in the Canadian context of a single-payer government healthcare program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.002DOI Listing
April 2019
4 Reads
2.351 Impact Factor

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Leuk Res 2019 Feb 7;77:42-50. Epub 2019 Jan 7.

Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL, United States. Electronic address:

Despite advances in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), overall survival rates remain low. The ability to predict treatment response based on individual cancer genomics using computational modeling will aid in the development of novel therapeutics and personalize care. Here, we used a combination of genomics, computational biology modeling (CBM), ex vivo chemosensitivity assay, and clinical data from 100 randomly selected patients in the Beat AML project to characterize AML sensitivity to a bromodomain (BRD) and extra-terminal (BET) inhibitor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183047
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442457PMC
February 2019
15 Reads

Involvement of pRb-E2F pathway in green tea extract-induced growth inhibition of human myeloid leukemia cells.

Leuk Res 2019 Feb 2;77:34-41. Epub 2019 Jan 2.

Department of Biology, College of Arts & Sciences, Barry University, Miami Shores, Florida 33161, USA. Electronic address:

Both inhibitory and stimulatory effect of EGCG on cancer cells have been reported, which often is linked to receptor tyrosine kinase signaling. In this study, we present evidence that green tea extract and its chemical component, Epigallocatechin-3-gallate (EGCG), inhibit growth of human myeloid leukemia cells through the regulation of pRb synthesis and formation of pRb-E2F complexes. Addition of green tea extract to the culture of TF-1a and MV4-11 myeloid leukemia cells significantly inhibited their proliferation with a substantial portion of cell death being observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.014DOI Listing
February 2019
11 Reads

Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.

Leuk Res 2019 Mar 7;78:3-11. Epub 2019 Jan 7.

Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL, USA. Electronic address:

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive hematological malignancy for which optimal therapeutic approaches are poorly characterized. Using computational biology modeling (CBM) in conjunction with genomic data from cell lines and individual patients, we generated disease-specific protein network maps that were used to identify unique characteristics associated with the mutational profiles of ETP-ALL compared to non-ETP-ALL (T-ALL) cases and simulated cellular responses to a digital library of FDA-approved and investigational agents. Genomics-based classification of ETP-ALL patients using CBM had a prediction sensitivity and specificity of 93% and 87%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.003DOI Listing
March 2019
5 Reads
2.351 Impact Factor

Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma.

Leuk Res 2019 Mar 3;78:1-2. Epub 2019 Jan 3.

Haematology-Pathology Research Laboratory, Odense University Hospital, Denmark; Department of Haematology, Odense University Hospital, Denmark. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.001DOI Listing
March 2019
2 Reads

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.

Leuk Res 2019 Feb 24;77:30-33. Epub 2018 Dec 24.

Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Indianapolis, IN, USA; Veterans Affairs Medical Center, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.011DOI Listing
February 2019
1 Read

Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.

Leuk Res 2019 Feb 24;77:28-29. Epub 2018 Dec 24.

Department of Haematology, St. James's Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.010DOI Listing
February 2019
2 Reads

Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.

Leuk Res 2019 Feb 21;77:17-27. Epub 2018 Dec 21.

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address:

Tropolones are naturally occurring seven-membered non-benzenoid aromatic compounds that are of interest due to their cytotoxic properties. MO-OH-Nap is a novel α-substituted tropolone that induces caspase cleavage and upregulates markers associated with the unfolded protein response (UPR) in multiple myeloma (MM) cells. Given previous reports that tropolones may function as iron chelators, we investigated the effects of MO-OH-Nap, as well as the known iron chelator deferoxamine (DFO), in MM cells in the presence or absence of supplemental iron. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456044PMC
February 2019
1 Read

A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia.

Leuk Res 2019 Feb 23;77:14-16. Epub 2018 Dec 23.

Department of Hematology& Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183050
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.009DOI Listing
February 2019
4 Reads

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

Leuk Res 2019 Feb 28;77:8-13. Epub 2018 Dec 28.

University of Rochester Medical Center, Department of Pathology, Hematopathology Unit and James P. Wilmot Cancer Institute, Rochester, NY, USA.

In patients with myelodysplastic syndromes (MDS) the impact of the percentage of erythroid precursors in the bone marrow has been the subject of considerable debate, especially with regard to prognosis. We examined the prognostic impact of the percentage of erythroid cells in the bone marrow (bmery) in 2453 primary untreated MDS patients in a retrospective multi-center analysis. Bmery were quantified in bone marrow smears at the time of diagnosis and were correlated with overall survival (OS) and AML evolution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.012DOI Listing
February 2019
3 Reads

Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma.

Leuk Res 2019 Feb 22;77:5-7. Epub 2018 Dec 22.

Unit of Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.008DOI Listing
February 2019
2.351 Impact Factor

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.

Leuk Res 2019 Feb 19;77:1-4. Epub 2018 Dec 19.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.006DOI Listing
February 2019
3 Reads

Transplantation for TP53 mutant MDS: Room for improvement.

Authors:
Dries Deeren

Leuk Res 2019 Jan 14;76:82-83. Epub 2018 Dec 14.

Department of haematology, AZ Delta, Roeselare, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.004DOI Listing
January 2019

The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.

Leuk Res 2019 Jan 11;76:76-81. Epub 2018 Dec 11.

Department of Hematology/Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:

Background: Severe thrombocytopenia affects 10% of patients with myelodysplastic syndrome (MDS) and is associated with poor outcomes. The role for prophylactic platelet transfusions in the outpatient setting is unknown.

Objective/methods: To audit treatments, bleeding rates, and transfusion requirements of patients with MDS and persistent severe thrombocytopenia (PST) registered in a prospective MDS registry at our center. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.002DOI Listing
January 2019
13 Reads

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Leuk Res 2019 Jan 4;76:70-75. Epub 2018 Dec 4.

Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Germline mutation in GATA2 can lead to GATA2 deficiency characterized by a complex multi-system disorder that can present with many manifestations including variable cytopenias, bone marrow failure, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and severe immunodeficiency. Penetrance and expressivity within families is often variable. There is a spectrum of bone marrow disease in symptomatic cytopenic patients ranging from hypocellular marrows without overt dysplasia to those with definitive MDS, AML, or chronic myelomonocytic leukemia. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340496PMC
January 2019
14 Reads

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Leuk Res 2019 Jan 4;76:65-69. Epub 2018 Dec 4.

Dipartimento di Biotecnologie Cellulari ed Ematologia, Università Sapienza, Roma, Italy.

Few data are available on the treatment with DFX in patients with transfusion dependent Ph- Myeloproliferative Neoplasms in fibrotic phase. Here we report 48MPNpatients and iron overload treated with DFX. Starting DFX dose was 20 mg/Kg in 23 patients, 15 mg/Kg in 20 patientsand 10 mg/Kg in 5 patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.012DOI Listing
January 2019
19 Reads